Drug intelligence / Profile preview

arginine + hydroxyurea

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

A combination of arginine and hydroxyurea being investigated for treatment of sickle cell disease. Hydroxyurea increases fetal hemoglobin (HbF) synthesis through a nitric oxide (NO)-cGMP pathway, while arginine serves as the main precursor of nitric oxide. The combination aims to enhance HbF production and reduce sickle cell formation more effectively than hydroxyurea alone. Laboratory studies have shown that specific combinations of hydroxyurea with arginine can increase HbF synthesis while minimizing cytotoxicity compared to hydroxyurea alone.

Targets

RNR (Ribonucleotide reductase)NOS1 (nNOS)

Beyond the preview

Go deeper on arginine + hydroxyurea.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on arginine + hydroxyurea.

Explore the full profile